Shubeck S.P. Morrow M. Dossett L.A.

De-escalation in breast cancer surgery.

NPJ Breast Cancer. 8: 25

De-escalating breast cancer surgery-where is the tipping point?.

JAMA Oncol. 6: 183-184Giuliano A.E. Hunt K. Blalman K. et al.

Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.

JAMA. 305: 569-575Sparano J.A. Gray R.J. Makower D. et al.

Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.

N Engl J Med. 379: 111-121Kalinsky K. Barlow W. Gralow J. et al.

21-gene assay to inform chemotherapy benefit in node-positive breast cancer.

N Engl J Med. 385: 2336-2347Kunkler I.H. Williams L. Jack W. et al.

Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.

Lancet Oncol. 16: 266-273Wang T. Baskin A.S. Dossett L.A.

Deimplementation of the choosing wisely recommendations for low-value breast cancer surgery: a systematic review.

JAMA Surg. 155: 759-770Veronesi U. Luini A. Galimberti V. et al.

Conservation approaches for the management of stage I/II carcinoma of the breast: milan cancer institute trials.

World J Surg. 18: 70-75

Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials.

N Engl J Med. 333: 1444-1455Fisher B. Anderson S. Bryant J. et al.

Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

N Engl J Med. 347: 1233-1241Veronesi U. Cascinelli N. Mariani L. et al.

Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.

N Engl J Med. 347: 1227-1232Wapnir I.L. Dignam J. Fisher B. et al.

Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

J Natl Cancer Inst. 103: 478-488Donker M. Litiere S. Werutsky G. et al.

Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial.

J Clin Oncol. 31: 4054-4059Wolmark N. Wang J. Mamounas E. et al.

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.

J Natl Cancer Inst Monogr. : 96-102van der Hage J.A. Van de Velde C. Julien J. et al.

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

J Clin Oncol. 19: 4224-4237Mieog J.S. van der Hage J.A. van de Velde C.J.

Neoadjuvant chemotherapy for operable breast cancer.

Br J Surg. 94: 1189-1200Moran M.S. Schnitt S. Giuliano A. et al.

Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.

Ann Surg Oncol. 21: 704-716Wang T. Bredbeck B. Sinco B. et al.

Variations in persistent use of low-value breast cancer surgery.

JAMA Surg. 156: 353-362Morrow M. Abrahamse P. Hofer T. et al.

Trends in reoperation after initial lumpectomy for breast cancer: addressing overtreatment in surgical management.

JAMA Oncol. 3: 1352-1357Bhutiani N. Mercer M. Bachman K. et al.

Evaluating the effect of margin consensus guideline publication on operative patterns and financial impact of breast cancer operation.

J Am Coll Surg. 227: 6-11Marinovich M.L. Noguchi N. Morrow M. et al.

Changes in reoperation after publication of consensus guidelines on margins for breast-conserving surgery: a systematic review and meta-analysis.

JAMA Surg. 155: e203025Hughes K.S. Schnaper K. Berry D. et al.

Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.

J Clin Oncol. 31: 2382-2387Kim T. Giuliano A.E. Lyman G.H.

Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis.

Cancer. 106: 4-16Veronesi U. Viale G. Paganelli G. et al.

Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study.

Ann Surg. 251: 595-600Krag D.N. Anderson S. Julian T. et al.

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.

Lancet Oncol. 11: 927-933Boughey J.C. Suman V. Mittendorf E. et al.

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

JAMA. 310: 1455-1461Kuehn T. Bauerfeind I. Fehm T. et al.

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

Lancet Oncol. 14: 609-618Tan V.K. Goh B. Fook-Chong S. et al.

The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer--a systematic review and meta-analysis.

J Surg Oncol. 104: 97-103Tee S.R. Devane L. Evoy D. et al.

Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer.

Br J Surg. 105: 1541-1552Pesce C. Liederback E. Wang C. et al.

Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.

Ann Surg Oncol. 21: 3231-3239Metcalfe K.A. Gershman S. Ghadirian P. et al.

Frequency of contralateral prophylactic mastectomy in breast cancer patients with a negative BRCA1 and BRCA2 rapid genetic test result.

Ann Surg Oncol. 28: 4967-4973Francis A. Fallowfield L. Rea D.

The LORIS trial: addressing overtreatment of ductal carcinoma in situ.

Clin Oncol (R Coll Radiol). 27: 6-8Kanbayashi C. Thompson A. Hwang E. et al.

The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA).

J Clin Oncol. 37: TPS603Hwang E.S. Hyslop T. Lynch T. et al.

The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).

BMJ Open. 9: e026797

Francis A., Bartlett J., Billingham L., et al., Abstract OT2-3-01: The LORIS trial: A multicentre, randomized phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ. San Antonio Breast Symposium, San Antonio, TX. 2013.

Sun S. Van la Parra R. Rauch G. et al.

Patient selection for clinical trials eliminating surgery for HER2-positive breast cancer treated with neoadjuvant systemic therapy.

Ann Surg Oncol. 26: 3071-3079Heil J. Pfob A. Kuerer H.M.

De-escalation towards omission is the tipping point of individualizing breast cancer surgery.

Eur J Surg Oncol. 46: 1543-1545Sparano J.A. Gray R. Makower D. et al.

Prospective validation of a 21-gene expression assay in breast cancer.

N Engl J Med. 373: 2005-2014Andre F. Ismaila N. Henry N. et al.

Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx.

J Clin Oncol. 37: 1956-1964

Kalinsky K, B.W., Meric-Bernstam F et al., SWOG S1007: Adjuvant trial randomized ER+ patients who had a recurrence score <25 and 1–3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy. Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS): San Antonio, TX, December 8–11, 2020. Abstract GS3-01.

Postmenopausal Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Risk of Recurrence Can Safely Forego Chemotherapy.

Oncologist. 26: S11-S12

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy. 2022.

Wang S.L. Fang H. Song Y. et al.

Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.

Lancet Oncol. 20: 352-360Liu L. Yang Y. Guo Q. et al.

Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review.

Radiat Oncol. 15: 17Dawood S. Lei X. Dent R. et al.

Survival of women with inflammatory breast cancer: a large population-based study.

Ann Oncol. 25: 1143-1151Stearns V. Ewing C. Slack R. et al.

Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.

Ann Surg Oncol. 9: 235-242

Pregnancy associated breast cancer.

Breast J. 26: 81-85

Pregnancy-associated breast cancer.

Clin Obstet Gynecol. 59: 779-788Katz S.J. Jagsi R. Morrow M.

Reducing overtreatment of cancer with precision medicine: just what the doctor ordered.

JAMA. 319: 1091-1092Norton W.E. Chambers D.A. Kramer B.S.

Conceptualizing de-implementation in cancer care delivery.

J Clin Oncol. 37: 93-96Giuliano A.E. Boolbol S. Degnim A. et al.

Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007.

Ann Surg Oncol. 14: 2425-2427Smith M.E. Vitous C. Hughes T. et al.

Barriers and Facilitators to De-Implementation of the Choosing Wisely(®) Guidelines for Low-Value Breast Cancer Surgery.

Ann Surg Oncol. 27: 2653-2663Andrews C. Childers T. Wiseman K. et al.

Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates.

BMC Cancer. 22: 141Greenup R.A. Rushing C. Fish L. et al.

Financial costs and burden related to decisions for breast cancer surgery.

J Oncol Pract. 15: e666-e676Berlin N.L. Skolarus T. Kerr E. et al.

Too much surgery: overcoming barriers to deimplementation of low-value surgery.

Ann Surg. 271: 1020-1022